Edgar Sánchez-Uribe1, Marcelino Esparza-Aguilar2, Umesh D Parashar3, Vesta Richardson1. 1. Ministry of Health, State of Morelos, Cuernavaca. 2. National Center for Child and Adolescent Health, Ministry of Health, Faculty of Medicine, National Autonomous University of Mexico, Mexico City. 3. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND: Mexico implemented routine childhood vaccination against rotavirus in 2007. We describe trends in hospitalization and deaths from diarrhea among children aged <5 years in Mexico before and 7 years after implementation of rotavirus vaccination. METHODS: We obtained data on deaths and hospitalizations from diarrhea, from January 2003 through December 2014, in Mexican children <5 years of age. We compared diarrhea-related mortality and hospitalizations in the postvaccine era with the prevaccine baseline from 2003 to 2006. RESULTS: Compared with the prevaccine baseline, we observed a 53% reduction (95% confidence interval [CI], 47%-58%) in diarrhea-related mortality and a 47% reduction (95% CI, 45%-48%) in diarrhea-related hospitalizations in postvaccine years, translating to 959 deaths and 5831 hospitalizations averted every year in Mexican children aged <5 years. Prevaccine peaks in diarrhea-related mortality and hospitalizations during the rotavirus season months were considerably diminished in postvaccine years, with greater declines observed during the rotavirus season compared with non-rotavirus season months. CONCLUSIONS: We document a substantial and sustained decline in diarrhea-related hospitalizations and deaths in Mexican children associated with implementation of rotavirus vaccination. These results highlight the public health benefits that could result in countries that adopt rotavirus vaccination into their national immunization programs.
BACKGROUND: Mexico implemented routine childhood vaccination against rotavirus in 2007. We describe trends in hospitalization and deaths from diarrhea among children aged <5 years in Mexico before and 7 years after implementation of rotavirus vaccination. METHODS: We obtained data on deaths and hospitalizations from diarrhea, from January 2003 through December 2014, in Mexican children <5 years of age. We compared diarrhea-related mortality and hospitalizations in the postvaccine era with the prevaccine baseline from 2003 to 2006. RESULTS: Compared with the prevaccine baseline, we observed a 53% reduction (95% confidence interval [CI], 47%-58%) in diarrhea-related mortality and a 47% reduction (95% CI, 45%-48%) in diarrhea-related hospitalizations in postvaccine years, translating to 959 deaths and 5831 hospitalizations averted every year in Mexican children aged <5 years. Prevaccine peaks in diarrhea-related mortality and hospitalizations during the rotavirus season months were considerably diminished in postvaccine years, with greater declines observed during the rotavirus season compared with non-rotavirus season months. CONCLUSIONS: We document a substantial and sustained decline in diarrhea-related hospitalizations and deaths in Mexican children associated with implementation of rotavirus vaccination. These results highlight the public health benefits that could result in countries that adopt rotavirus vaccination into their national immunization programs.
Authors: Negar Aliabadi; Sébastien Antoni; Jason M Mwenda; Goitom Weldegebriel; Joseph N M Biey; Dah Cheikh; Kamal Fahmy; Nadia Teleb; Hossam Abdelrahman Ashmony; Hinda Ahmed; Danni S Daniels; Dovile Videbaek; Annemarie Wasley; Simarjit Singh; Lucia Helena de Oliveira; Gloria Rey-Benito; N Jennifer Sanwogou; Pushpa Ranjan Wijesinghe; Jayantha B L Liyanage; Batmunkh Nyambat; Varja Grabovac; James D Heffelfinger; Kimberley Fox; Fem Julia Paladin; Tomoka Nakamura; Mary Agócs; Jillian Murray; Thomas Cherian; Catherine Yen; Umesh D Parashar; Fatima Serhan; Jacqueline E Tate; Adam L Cohen Journal: Lancet Glob Health Date: 2019-07 Impact factor: 26.763
Authors: A D Steele; J C Victor; M E Carey; J E Tate; D E Atherly; C Pecenka; Z Diaz; U D Parashar; C D Kirkwood Journal: Hum Vaccin Immunother Date: 2019-02-08 Impact factor: 3.452
Authors: James A Platts-Mills; Caroline Amour; Jean Gratz; Rosemary Nshama; Thomas Walongo; Buliga Mujaga; Athanasia Maro; Timothy L McMurry; Jie Liu; Estomih Mduma; Eric R Houpt Journal: Clin Infect Dis Date: 2017-10-01 Impact factor: 9.079
Authors: Anna Lena Lopez; Peter Francis Raguindin; Joel Esparagoza; Kimberley Fox; Nyambat Batmunkh; Joseph Bonifacio; Umesh D Parashar; Jacqueline E Tate; Maria Joyce Ducusin Journal: Vaccine Date: 2018-05-03 Impact factor: 3.641